2. JAK/STAT Signaling Protein Tyrosine Kinase/RTK Antibody-drug Conjugate/ADC Related
  3. Radionuclide-Drug Conjugates (RDCs) EGFR ADC Antibody
  4. Trastuzumab

Trastuzumab  (Synonyms: Anti-Human HER2, Humanized Antibody)

Cat. No.: HY-P9907 Purity: 99.80%
COA
SDS
Technical Support

Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

CAS No. : 180288-69-1

사이즈 가격 재고 수량
1 mg 해외재고보유
5 mg 해외재고보유
10 mg 해외재고보유
25 mg 해외재고보유
50 mg 해외재고보유
100 mg   견적 받기  
200 mg   견적 받기  

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 55 publication(s) in Google Scholar

Other Forms of Trastuzumab:

Trastuzumab Related Antibodies

Top Publications Citing Use of Products

55 Publications Citing Use of MCE Trastuzumab

Gel Electrophoresis
ELISA
In Vivo Efficacy Study
Cell Proliferation/Viability Assay
IHC
WB

    Trastuzumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 4;16(1):6152.  [Abstract]

    ELISA analysis of same constructs with FcγRIIIA-V158 as immobilized antigen.

    Trastuzumab purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Mar 12;16(1):170.  [Abstract]

    Trastuzumab (100 ng/mL; 24-94 h) significantly downregulated MCL1 protein levels in HER2-amplified NCI-N87 (Fig. A) and SNU-216 (Fig. B) cells, but shows no such effect in HER2-nonamplified GCIY cells (Fig. C).

    Trastuzumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2023 Sep 14;14(1):5699.  [Abstract]

    Trastuzumab (TZB) (3.16-1000 nM; 14 h) is cytotoxic to GBC-SD and EH-GB1 cells.

    Trastuzumab purchased from MedChemExpress. Usage Cited in: Nat Commun. 2020 Feb 26;11(1):1049.   [Abstract]

    Trypsin microdroplet digestion of the therapeutic antibody Trastuzumab with ESSI-MS (−3 kV) after PAGE gel separation.

    Trastuzumab purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2020 Apr 10;475:53-64.  [Abstract]

    Cell viability was measured for cells as in shControl or shEphB4 for 9 days by crystal violet assays.

    Trastuzumab purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2020 Apr 10;475:53-64.  [Abstract]

    Western blot analysis of proteins as indicated in shControl or shEphB4 expressing HCC1954 cells treated with or without Transtuzumab (30 mg/mL) for 72 hours.

    Trastuzumab purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 22;38(1):214.  [Abstract]

    Tumours obtained from mice injected subcutaneously with HGC-27 cells with either over- or normal expression of GPAA1 and treated with vehicle or Trastuzumab (25 mg/kg, twice daily, 35 days).

    Trastuzumab purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2019 May 22;38(1):214.  [Abstract]

    IHC staining of GPAA1, p-AKT and Ki-67 in each group treated with vehicle or Trastuzumab (25 mg/kg, twice daily, 35 days).

    View All Radionuclide-Drug Conjugates (RDCs) Isoform Specific Products:

    View All Isoforms
    RDC Peptide RDC Antibody RDC Bifunctional Chelator RDC Linker Other

    View All EGFR Isoform Specific Products:

    View All Isoforms
    EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

    • Biological Activity

    • Protocol

    • 순도&문서

    • References

    • 고객리뷰

    제품 설명

    Trastuzumab is a humanized IgG1 monoclonal antibody that selectively binds to HER2 with high affinity. Trastuzumab can be used for the research of HER2-positive metastatic breast cancer and gastric cancer[1][2][3]. (Note: The product specifications below only indicate the effective content of Trastuzumab. The component ratio of this product is Trastuzumab : excipients = 1:0.6-1:0.9.)

    Isotype

    Human IgG1 kappa
    Recommend Isotype Controls
    Species Reactivity

    Human
    IC50 & Target[1]

    RDC Antibody

     

    HER2

     

    In Vitro

    Treatment of HER2-overexpressing breast cancer cell lines with Trastuzumab results in induction of p27KIP1 and the Rb-related protein, p130, which in turn significantly reduces the number of cells undergoing S-phase. A number of other phenotypic changes are observed in vitro as a consequence of Trastuzumab binding to HER2-overexpressing cells. Interaction of Trastuzumab with the human immune system via its human immunoglobulin G1 Fc domain may potentiate its antitumor activities. in vitro studies demonstrate that Trastuzumab is very effective in mediating antibody-dependent cell-mediated cytotoxicity against HER2-overexpressing tumor targets[1]. Trastuzumab consists of two antigen-specific sites that bind to the juxtamembrane portion of the extracellular domain of the HER2 receptor and that prevent the activation of its intracellular tyrosine kinase. Trastuzumab recruits immune effector cells that are responsible for antibody-dependent cytotoxicity[2]. The presence of Trastuzumab IgG significantly increases killing of all breast cancer cell lines. The ADCC activity of PBMCs evoked by Trastuzumab is equally strong against Trastuzumab-sensitive (SKBR-3) or Trastuzumab-resistant (JIMT-1) breast cancer cells, with dose-dependent cell death reaching 50–60% killing at an effector/target ratio of 60:1[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Trastuzumab Related Antibodies
    In Vivo

    Trastuzumab treatment of mouse xenograft models results in marked suppression of tumor growth. When given in combination with standard cytotoxic chemotherapeutic agents, Trastuzumab treatment generally results in statistically superior antitumor efficacy compared with either agent given alone[1]. Trastuzumab causes a significant growth inhibition of the outgrowth of macroscopic JIMT-1 xenograft tumors in both nude and SCID mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    Gene ID

    2064  [NCBI]

    Accession
    Application

    ELISA, FACS, Functional assay
    Conjugated

    Unconjugated
    Reconsititution

    The product can be reconstituted/diluted with sterile PBS or saline.
    분자량

    145.36 kDa

    CAS No.
    Appearance

    Solid

    Color

    White to light yellow

    SMILES

    [Trastuzumab]
    Formulation

    Please refer to the lot-specific COA for specific buffer information.
    보관

    Please store the product under the recommended conditions in the Certificate of Analysis.
    Format
    • Human IgG1 kappa
    Biological Activity
    • Loaded Trastuzumab on AHC2 biosensor, can bind Her2/CD340 Protein, Human (Biotinylated, HEK293, His, HY-P78882) with an affinity constant of 6.903E-10 M as determined in BLI assay.
    • Trastuzumab has a significant ADCC effect on BT474 cells in a dose-dependent manner.The EC50 for this effect is 26.36 and 32.09 ng/mL.
    • Trastuzumab has a significant ADCC effect on SK-BR-3 cells in a dose-dependent manner.The EC50 for this effect is 14.43 and 16.70 ng/mL.
    • Immobilized HER2/CD340 Protein, Human (630a.a, HEK293, His, HY-P70254) can bind Trastuzumab.The EC50 for this effect is 2.16 ng/mL.
    순도&문서

    Purity: 99.80%

    SDS (419 KB)

    COA (232 KB)

    Inhibitory Antibodies User Guide (603 KB)
    References
    Cell Assay 
    [3]

    The effects of Trastuzumab and Trastuzumab-F(ab′)2 on the growth of JIMT-1, SKBR-3, and BT-474 cells are evaluated using the AlamarBlue method. Exponentially growing cells are harvested and plated in single wells of a 96-well flat-bottomed tissue culture plate at defined densities, ranging from 4,500-8,000 cells per well depending on the cell line. After overnight culture, the regular medium is exchanged to medium containing 0, 1, 10, or 100 μg/mL Trastuzumab or Trastuzumab-F(ab′) 2. Cell viability is tested after 72 h of treatment. Fluorescence is detected at an excitation of 544 nm, and emission is detected at 590 nm[3].

    MCE 는 독립적으로 이러한 방법들의 정확성을 확인하지 않았습니다. 참고용으로만 봐주십시오.
    Animal Administration
    [3]

    Trastuzumab and Trastuzumab-F(ab′)2 are given at a dose of 5 and 25 μg/g, respectively, by weekly i.p. injection. The five times greater amount of administered F(ab′)2 is chosen based on the different half-lives of IgG and F(ab′) F(ab′)2. Control mice are treated with weekly i.p. injection of 100 μL physiologic saline (saline). Animals are euthanized by CO2 inhalation[3].

    MCE 는 독립적으로 이러한 방법들의 정확성을 확인하지 않았습니다. 참고용으로만 봐주십시오.
    References
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Trastuzumab Related Classifications

    • 몰농도 계산기

    • 농도 희석 계산기

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass   Concentration   Volume   Molecular Weight *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Trastuzumab180288-69-1Anti-Human HER2, Humanized AntibodyRadionuclide-Drug Conjugates (RDCs)EGFRADC AntibodyEpidermal growth factor receptorErbB-1HER1Inhibitorinhibitorinhibit

    최근 본 상품:

    온라인 문의

    Your information is safe with us. * Required Fields.

    상품명

    		  

    Requested Quantity *

    고객명 *

    		 

    호칭

    메일주소 *

    		 

    전화번호 *

    Department

    		 

    회사명 *

    City

    도

    Country or Region *

    		      

    비고

    대량구매 문의

    Inquiry Information

    상품명:
    Trastuzumab
    Cat. No.:
    HY-P9907
    수량:
    MCE Japan Authorized Agent:

    고객리뷰

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    상품명

    		  

    Lot #

    고객명 *

    		 

    메일주소 *

    전화번호

    		 

    Department *

    회사명 *

    		 

    Country or Region *

    비고

    SAFETY DATA SHEET (SDS)

    English - EN (419 KB) Français - FR (419 KB) Deutsch - DE (419 KB) Norwegian - NO (419 KB) Español - ES (419 KB) Swedish - SV (419 KB) Italian - IT (419 KB) Korean - KR (419 KB) Portuguese - PT (419 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.